ReviewInternational journal of clinical and experimental medicine2015
Biomarkers of head and neck cancer, tools or a gordian knot?
Review in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- Long Noncoding RNA MALAT1 Promotes Laryngocarcinoma Development by Targeting miR-708-5p/BRD4 Axis to Regulate YAP1-Mediated Epithelial-Mesenchymal Transition.BioMed research international · 2022Article
- Article
- LncRNAIranian journal of public health · 2021Article
- Association Between Interleukin-6 and Head and Neck Squamous Cell Carcinoma: A Systematic Review.Clinical and experimental otorhinolaryngology · 2021Review
- HPV Meets APOBEC: New Players in Head and Neck Cancer.International journal of molecular sciences · 2021Review
- IL6 and BCL3 Expression Are Potential Biomarkers in Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
- Article
- Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas.The Laryngoscope · 2020Article
- miR-552 promotes laryngocarcinoma cells proliferation and metastasis by targeting p53 pathway.Cell cycle (Georgetown, Tex.) · 2020Article
- E2F6-Mediated Downregulation of MIR22HG Facilitates the Progression of Laryngocarcinoma by Targeting the miR-5000-3p/FBXW7 Axis.Molecular and cellular biology · 2020Article
- Standardised Ki-67 proliferation index assessment in early-stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapy.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2020Article
- PYHIN Proteins and HPV: Role in the Pathogenesis of Head and Neck Squamous Cell Carcinoma.Microorganisms · 2019Review
- Combined expression and prognostic significance of PPFIA1 and ALG3 in head and neck squamous cell carcinoma.Molecular biology reports · 2019Article
- PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.Molecular biology reports · 2019Article
- MiR-29a-3p suppresses cell proliferation in laryngocarcinoma by targeting prominin 1.FEBS open bio · 2017Article
- Updated overview of current biomarkers in head and neck carcinoma.World journal of methodology · 2016Review
- Clinical, Histological and Immunohistochemical Evaluation of Larynx Cancer.Current health sciences journalArticle
- The evaluation of pretreatment neutrophil-lymphocyte ratio and derived neutrophil-lymphocyte ratio in patients with laryngeal neoplasms.Brazilian journal of otorhinolaryngologyArticle
- SKA1 is overexpressed in laryngocarcinoma and modulates cell growth via P53 signaling pathway.Cell cycle (Georgetown, Tex.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck tumors comprise a wide spectrum of heterogeneous neoplasms for which biomarkers are needed to aid in earlier diagnosis, risk assessment and therapy response. Personalized medicine based on predictive markers linked to drug response, it is hoped, will lead to improvements in outcomes and avoidance of unnecessary treatment in carcinoma of the head and neck. Because of the heterogeneity of head and neck tumors, the integration of multiple selected markers in association with the histopathologic features is advocated for risk assessment. Validation of each biomarker in the context of clinical trials will be required before a specific marker can be incorporated into daily practice. Furthermore, we will give evidence that some proteins implicated in cell-cell interaction, such as CD44 may be involved in the multiple mechanism of the development and progression of laryngeal lesions and may help to predict the risk of transformation of the benign or precancerous lesions to cancer.
Indexed as
Identifiers
26379825PMC4565208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.